| Year |
Citation |
Score |
| 2019 |
Gregory MA, Nemkov T, Park HJ, Zaberezhnvv V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting glutamine metabolism and redox state for leukemia therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30940653 DOI: 10.1158/1078-0432.Ccr-18-3223 |
0.304 |
|
| 2017 |
Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D'Alessandro A, DeGregori J. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Experimental Hematology. PMID 28947392 DOI: 10.1016/J.Exphem.2017.09.007 |
0.362 |
|
| 2016 |
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 113: E6669-E6678. PMID 27791036 DOI: 10.1073/Pnas.1603876113 |
0.361 |
|
| 2015 |
Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1360-72. PMID 25547679 DOI: 10.1158/1078-0432.Ccr-14-2146 |
0.338 |
|
| 2015 |
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Tan AC, Hansen KC, DeGregori J. Abstract C78: ATM/G6PD-dependent metabolic pathways promote mitochondrial redox homeostasis and resistance to FLT3 inhibition in acute myeloid leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C78 |
0.417 |
|
| 2014 |
Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. American Journal of Hematology. 89: 896-903. PMID 24891015 DOI: 10.1002/Ajh.23776 |
0.342 |
|
| 2013 |
Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4149-62. PMID 23757356 DOI: 10.1158/1078-0432.Ccr-12-3140 |
0.337 |
|
| 2013 |
Zhang Q, Spears E, Boone DN, Li Z, Gregory MA, Hann SR. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. Proceedings of the National Academy of Sciences of the United States of America. 110: 978-83. PMID 23277542 DOI: 10.1073/Pnas.1208334110 |
0.758 |
|
| 2013 |
Alvarez-Calderon F, Gregory MA, DeGregori J. Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunologic Research. 55: 100-15. PMID 22941562 DOI: 10.1007/S12026-012-8353-Z |
0.335 |
|
| 2012 |
Nifoussi SK, Vrana JA, Domina AM, De Biasio A, Gui J, Gregory MA, Hann SR, Craig RW. Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. Plos One. 7: e47060. PMID 23056582 DOI: 10.1371/Journal.Pone.0047060 |
0.675 |
|
| 2012 |
Alvarez-Calderon F, Zaberezhnyy V, Gemta L, Gregory MA, DeGregori JV. Abstract 1127: Bcr-Abl inhibition in leukemia cells creates metabolic addictions Cancer Research. 72: 1127-1127. DOI: 10.1158/1538-7445.Am2012-1127 |
0.358 |
|
| 2011 |
Alvarez-Calderon F, Gregory MA, DeGregori J. Abstract 3796: Inhibition of mitochondrial respiration synergizes with tyrosine kinase inhibitors to eliminate Bcr-Abl+ leukemia Cancer Research. 71: 3796-3796. DOI: 10.1158/1538-7445.Am2011-3796 |
0.366 |
|
| 2010 |
Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 18: 74-87. PMID 20609354 DOI: 10.1016/J.Ccr.2010.04.025 |
0.344 |
|
| 2006 |
Wilkinson B, Gregory MA, Moss SJ, Carletti I, Sheridan RM, Kaja A, Ward M, Olano C, Mendez C, Salas JA, Leadlay PF, vanGinckel R, Zhang MQ. Separation of anti-angiogenic and cytotoxic activities of borrelidin by modification at the C17 side chain. Bioorganic & Medicinal Chemistry Letters. 16: 5814-7. PMID 16962775 DOI: 10.1016/J.Bmcl.2006.08.073 |
0.315 |
|
| 2005 |
Gregory MA, Qi Y, Hann SR. The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle (Georgetown, Tex.). 4: 249-52. PMID 15655352 DOI: 10.4161/Cc.4.2.1491 |
0.742 |
|
| 2004 |
Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature. 431: 712-7. PMID 15361884 DOI: 10.1038/Nature02958 |
0.751 |
|
| 2004 |
Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 23: 5301-15. PMID 15241487 DOI: 10.1038/Sj.Onc.1207692 |
0.661 |
|
| 2003 |
Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. The Journal of Biological Chemistry. 278: 51606-12. PMID 14563837 DOI: 10.1074/Jbc.M310722200 |
0.748 |
|
| 2000 |
Gregory MA, Xiao Q, Cornwall GA, Lutterbach B, Hann SR. B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation. Oncogene. 19: 4886-95. PMID 11039906 DOI: 10.1038/Sj.Onc.1203851 |
0.667 |
|
| 2000 |
Niklinski J, Claassen G, Meyers C, Gregory MA, Allegra CJ, Kaye FJ, Hann SR, Zajac-Kaye M. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Molecular and Cellular Biology. 20: 5276-84. PMID 10866684 DOI: 10.1128/Mcb.20.14.5276-5284.2000 |
0.699 |
|
| 2000 |
Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Molecular and Cellular Biology. 20: 2423-35. PMID 10713166 DOI: 10.1128/Mcb.20.7.2423-2435.2000 |
0.753 |
|
| Show low-probability matches. |